{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:44:15Z","timestamp":1790307855636,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI106878"],"award-info":[{"award-number":["AI106878"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI177075"],"award-info":[{"award-number":["AI177075"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI155414"],"award-info":[{"award-number":["AI155414"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"John E Fogarty International Center","doi-asserted-by":"publisher","award":["TW005572"],"award-info":[{"award-number":["TW005572"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"John E Fogarty International Center","doi-asserted-by":"publisher","award":["TW010362"],"award-info":[{"award-number":["TW010362"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.vaccine.2024.126263","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T22:23:55Z","timestamp":1725143035000},"page":"126263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge"],"prefix":"10.1016","volume":"42","author":[{"given":"Meagan","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeshina","family":"Janardhanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanchal","family":"Wagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smriti","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richelle C.","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Kamruzzaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchir Kumar","family":"Pansuriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahima","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willie F.","family":"Vann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraful Islam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taufiqur Rahman","family":"Bhuiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firdausi","family":"Qadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavol","family":"Kov\u00e1\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward T.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.vaccine.2024.126263_bb0005","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1473-3099(18)30475-4","article-title":"Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the global burden of disease study 1990-2016","volume":"18","author":"Khalil","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2024.126263_bb0010","first-page":"651","article-title":"Global burden of Shigella infections: implications for vaccine development and implementation of control strategies","volume":"77","author":"Kotloff","year":"1999","journal-title":"Bull World Health Organ"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126263_bb0015","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.pcl.2017.03.006","article-title":"The burden and etiology of diarrheal illness in developing countries","volume":"64","author":"Kotloff","year":"2017","journal-title":"Pediatr Clin N Am"},{"issue":"10053","key":"10.1016\/j.vaccine.2024.126263_bb0020","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015","volume":"388","author":"Mortality","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2024.126263_bb0025","article-title":"The Shigella Vaccines Pipeline","volume":"10","author":"MacLennan","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126263_bb0030","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/infdis\/157.5.1068","article-title":"Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population","volume":"157","author":"Cohen","year":"1988","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126263_bb0035","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1086\/516452","article-title":"Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection","volume":"175","author":"Robin","year":"1997","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126263_bb0040","article-title":"Detoxified O-Specific Polysaccharide (O-SP)-Protein Conjugates: Emerging Approach in the Shigella Vaccine Development Scene","volume":"10","author":"Cohen","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126263_bb0045","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1017\/S0950268814000260","article-title":"Recent trends in the epidemiology of shigellosis in Israel","volume":"142","author":"Cohen","year":"2014","journal-title":"Epidemiol Infect"},{"issue":"9046","key":"10.1016\/j.vaccine.2024.126263_bb0050","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(96)06255-1","article-title":"Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults","volume":"349","author":"Cohen","year":"1997","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126263_bb0055","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1128\/jcm.29.2.386-389.1991","article-title":"Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis","volume":"29","author":"Cohen","year":"1991","journal-title":"J Clin Microbiol"},{"issue":"8","key":"10.1016\/j.vaccine.2024.126263_bb0060","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.inf.0000078156.03697.a5","article-title":"Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children","volume":"22","author":"Passwell","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126263_bb0065","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/cid\/ciu468","article-title":"Shigella isolates from the global enteric multicenter study inform vaccine development","volume":"59","author":"Livio","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126263_bb0070","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrmicro1662","article-title":"Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road","volume":"5","author":"Levine","year":"2007","journal-title":"Nat Rev Microbiol"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126263_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009826","article-title":"Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. Flexneri serotypes","volume":"15","author":"Citiulo","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126263_bb0080","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126263_bb0085","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ebiom.2017.07.013","article-title":"Safety profile and immunologic responses of a novel vaccine against Shigella sonnei administered intramuscularly, Intradermally and Intranasally: results from two parallel randomized phase 1 clinical studies in healthy adult volunteers in Europe","volume":"22","author":"Launay","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2024.126263_bb0090","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3389\/fimmu.2017.01884","article-title":"A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB generalized modules for membrane antigen vaccine against Shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country","volume":"8","author":"Obiero","year":"2017","journal-title":"Front Immunol"},{"issue":"36","key":"10.1016\/j.vaccine.2024.126263_bb0095","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1016\/j.vaccine.2015.06.102","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: a single blind, partially randomized phase I study","volume":"33","author":"Hatz","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126263_bb0100","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/CVI.00224-16","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study","volume":"23","author":"Riddle","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126263_bb0105","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1021\/acs.bioconjchem.5b00617","article-title":"A Synthetic Carbohydrate Conjugate Vaccine Candidate against Shigellosis: Improved Bioconjugation and Impact of Alum on Immunogenicity","volume":"27","author":"van der Put","year":"2016","journal-title":"Bioconjug Chem"},{"issue":"32 Pt B","key":"10.1016\/j.vaccine.2024.126263_bb0110","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1016\/j.vaccine.2018.06.063","article-title":"A phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei","volume":"36","author":"Frenck","year":"2018","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126263_bb0115","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1128\/CVI.00665-15","article-title":"Clinical trial of an Oral live Shigella sonnei vaccine candidate, WRSS1, in Thai adults","volume":"23","author":"Pitisuttithum","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126263_bb0120","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/IAI.72.2.923-930.2004","article-title":"Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in north American volunteers","volume":"72","author":"Katz","year":"2004","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126263_bb0125","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1080\/21645515.2019.1575165","article-title":"A phase I trial of WRSS1, a Shigella sonnei live oral vaccine in Bangladeshi adults and children","volume":"15","author":"Raqib","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126263_bb0130","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4161\/hv.4746","article-title":"Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media","volume":"3","author":"Kotloff","year":"2007","journal-title":"Hum Vaccin"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126263_bb0135","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.vaccine.2010.10.035","article-title":"Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh","volume":"29","author":"Rahman","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126263_bb0140","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/CVI.00683-13","article-title":"Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine","volume":"21","author":"Kaminski","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126263_bb0145","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/CVI.00608-15","article-title":"Evaluation of the safety, tolerability, and immunogenicity of an Oral, inactivated whole-cell Shigella flexneri 2a vaccine in healthy adult subjects","volume":"23","author":"Chakraborty","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126263_bb0150","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00583-17","article-title":"Assembly, Biochemical characterization, immunogenicity, Adjuvanticity, and efficacy of Shigella artificial Invaplex","volume":"3","author":"Turbyfill","year":"2018","journal-title":"mSphere"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126263_bb0155","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1128\/IAI.68.12.6624-6632.2000","article-title":"Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine","volume":"68","author":"Turbyfill","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2024.126263_bb0160","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.01020-21","article-title":"Immunization of Rabbits with a Quadrivalent Shigella Bioconjugate Vaccine Induces Functional Antibodies Reactive with Shigella Isolates from Kenya","author":"Odundo","year":"2022","journal-title":"mSphere"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126263_bb0165","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1021\/acscentsci.1c01479","article-title":"The First-in-Human Synthetic Glycan-Based Conjugate Vaccine Candidate against Shigella","volume":"8","author":"van der Put","year":"2022","journal-title":"ACS Cent Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126263_bb0170","article-title":"Toward a Multivalent Synthetic Oligosaccharide-Based Conjugate Vaccine against Shigella: State-of-the-Art for a Monovalent Prototype and Challenges","volume":"10","author":"Phalipon","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126263_bb0175","article-title":"Safety and immunogenicity of a Shigella bivalent conjugate vaccine (ZF0901) in 3-month- to 5-year-old children in China","volume":"10","author":"Mo","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.126263_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103343","article-title":"Shigella conjugate vaccine efficacy trial in controlled human model and potential immune correlates of protection","volume":"66","author":"Raqib","year":"2021","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126263_bb0185","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(20)30488-6","article-title":"Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study","volume":"21","author":"Cohen","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"47","key":"10.1016\/j.vaccine.2024.126263_bb0190","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1016\/j.vaccine.2021.10.005","article-title":"Scalable production and immunogenicity of a cholera conjugate vaccine","volume":"39","author":"Jeon","year":"2021","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126263_bb0195","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1021\/bc2001984","article-title":"Simple, direct conjugation of bacterial O-SP-core antigens to proteins: development of cholera conjugate vaccines","volume":"22","author":"Xu","year":"2011","journal-title":"Bioconjug Chem"},{"issue":"8","key":"10.1016\/j.vaccine.2024.126263_bb0200","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/cbic.201600699","article-title":"Conjugate Vaccines from Bacterial Antigens by Squaric Acid Chemistry: A Closer Look","volume":"18","author":"Xu","year":"2017","journal-title":"Chembiochem"},{"issue":"34","key":"10.1016\/j.vaccine.2024.126263_bb0205","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1016\/j.vaccine.2023.06.052","article-title":"Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. Flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry","volume":"41","author":"Kelly","year":"2023","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126263_bb0210","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1128\/jcm.26.7.1343-1348.1988","article-title":"Congo red binding and salt aggregation as indicators of virulence in Shigella species","volume":"26","author":"Qadri","year":"1988","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126263_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003881","article-title":"A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice","volume":"9","author":"Sayeed","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2024.126263_bb0220","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1128\/CVI.00321-12","article-title":"Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera","volume":"19","author":"Johnson","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126263_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002683","article-title":"Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide","volume":"8","author":"Alam","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126263_bb0230","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0003-2697(88)90578-7","article-title":"Colorimetric determination of neutral sugars by a resorcinol sulfuric acid micromethod","volume":"175","author":"Monsigny","year":"1988","journal-title":"Anal Biochem"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126263_bb0235","article-title":"GMMA and Glycoconjugate Approaches Compared in Mice for the Development of a Vaccine against Shigella flexneri Serotype 6","volume":"8","author":"Raso","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"10.1016\/j.vaccine.2024.126263_bb0240","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.carres.2010.05.006","article-title":"Immunochemical studies of Shigella flexneri 2a and 6, and Shigella dysenteriae type 1 O-specific polysaccharide-core fragments and their protein conjugates as vaccine candidates","volume":"345","author":"Kubler-Kielb","year":"2010","journal-title":"Carbohydr Res"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126263_bb0245","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/glycob\/cwr088","article-title":"Lipopolysaccharide core structures and their correlation with genetic groupings of Shigella strains. A novel core variant in Shigella boydii type 16","volume":"21","author":"Knirel","year":"2011","journal-title":"Glycobiology"},{"issue":"37","key":"10.1016\/j.vaccine.2024.126263_bb0250","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1016\/j.vaccine.2017.07.070","article-title":"Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice","volume":"35","author":"Farzam","year":"2017","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126263_bb0255","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.4269\/ajtmh.20-1511","article-title":"Parenteral Vaccination with a Cholera Conjugate Vaccine Boosts Vibriocidal and Anti-OSP Responses in Mice Previously Immunized with an Oral Cholera Vaccine","volume":"104","author":"Akter","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2024.126263_bb0260","article-title":"Isolation, purification, characterization and direct conjugation of the lipid A-free lipopolysaccharide of Vibrio cholerae O139","author":"Xu","year":"2019","journal-title":"Chemistry"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24009459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24009459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T17:49:14Z","timestamp":1729014554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24009459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":52,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0264410X24009459"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126263","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126263"}}